What Semaglutide Dr. Is
Semaglutide Dr. is an independent editorial project that publishes summaries of the peer-reviewed research literature on semaglutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The name carries a "Dr." modifier. This is editorial framing — a position we occupy relative to the literature, signaling physician-grade rigor in how we read and present clinical trial data. It is not a claim about clinical services, a real person named "Dr. Something," or a medical practice. No clinicians are on staff. No consultations are offered.
The semaglutide literature is one of the most richly documented in contemporary pharmacology: the STEP, SUSTAIN, PIONEER, SELECT, FLOW, and ESSENCE trial programs, collectively involving more than 50,000 participants across randomized controlled trials published in the New England Journal of Medicine, JAMA, The Lancet, and Nature Medicine. This volume of evidence deserves a dedicated reading console — an organized, cited digest that presents what each trial actually measured without distorting it toward commerce or alarm.
Editorial Standards
Every quantitative claim on this site is cited to a named study with a DOI or PubMed URL. There are 24 primary citations across this console. Claims without a citation do not appear.
The compound class is FDA-approved; therefore this site describes labeled doses and approved indications as documented in the FDA label and the trial protocols. It does not recommend clinical use, does not prescribe, and does not recommend one formulation over another. Dosage information describes what was studied and at what regimen in which population — not what any reader should administer.
We do not invent citations, do not use secondary or tertiary sources where primary sources exist, and do not describe findings from unpublished or preprint-only work as established results. The citation auditor that reviewed this content before publication verified every URL and DOI.
What This Site Is Not
Not a clinic. Not a pharmacy. Not a prescribing service. Not a telehealth platform. Not a vendor. Not affiliated with any manufacturer, telehealth company, or pharmacy.
The editorial modifier "Dr." signals the standard of rigor applied to reading the literature — specifically: the habit of going to the primary source, noting the n-value, checking the confidence interval, and stating the finding as the trial measured it rather than as a headline generalization. It is a posture toward evidence, not a professional designation.
Consult a licensed physician for all clinical decisions about semaglutide or any prescription medication.